The PROTAC market is experiencing rapid growth, driven by rising interest in targeted protein degradation as a next-generation therapeutic approach. Expanding oncology pipelines with drugs in clinical ...
Total Revenues of $599 million for the Fourth Quarter of 2025, $2.320 billion for the Fiscal Year 2025 –– Cabozantinib Franchise Achieved $2.123 billion in U.S. Net Product Revenues for the Fiscal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results